Investigators from @danafarber.bsky.social have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates. Research in @nature.com builds on Ebert & Fischer Lab findings revealing potential to benefit patients w/ cancer. bit.ly/3RACm14
@danafarber.bsky.social & leading research institutions are unveiling 600+ new tissue models of human cancer. The Human Cancer Models Initiative described in @nature.com makes these models available to scientists around the globe to accelerate cancer treatments and drive discoveries. bit.ly/3TF6Mjd
Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by U.S. News & World Report. Learn more: bit.ly/3TDL9Qi
The @danafarber.bsky.social Department of Pathology has been awarded a $2.875 million grant over five years from the National Cancer Institute. Read more here: bit.ly/450oDDM
New research from @danafarber.bsky.social’s Sarah Hill, MD, PhD, reveals that as CDK4/6 inhibitors are being investigated as a possible treatment in endometrial cancer, RB function-predictive transcriptional signatures may be a relevant biomarker to help predict response to therapy. bit.ly/4wBUR4b
Zenocutuzumab offers a new, targeted treatment option for patients with previously treated, advanced NRG1 fusion-positive cholangiocarcinoma. @danafarber.bsky.social’s James Cleary, MD, PhD, discusses in Oncology Learning Network the approval & role of comprehensive molecular testing. bit.ly/4h0u3Wy
Zenocutuzumab Expands Targeted Treatment Options for NRG1 Fusion-Positive Cholangiocarcinoma
James Cleary, MD, PhD, discusses the recent FDA approval of zenocutuzumab for patients with NRG1 fusion–positive cholangiocarcinoma and the importance of incorporating RNA-based next-generation sequencing into routine molecular testing to identify patients who may benefit from this highly effective targeted therapy.
bit.ly
The Mass. Life Sciences Center and @massgovernor.bsky.social named @danafarber.bsky.social to the nation’s first statewide, disease-specific biobank program to support a #ColorectalCancer biobank. Kimmie Ng, MD, says the goal is to advance prevention, early detection, and treatment. bit.ly/4bl6G6s
Pregnancy poses unique challenges in diagnosing and treating colorectal cancer in young adult women. Dr. Kimmie Ng of @danafarber.bsky.social explains more in this article in @washingtonpost.com. ➡️bit.ly/4bPNDRR
Colorectal cancer is on the rise - and often overlooked - in this surprising group
As the disease strikes more young people, pregnant and postpartum women face an increasing risk of delayed diagnosis and poor outcomes.
bit.ly
Learn more about sarcomas, treatments and research trials from @danafarber.bsky.social at bit.ly/4yJQWDW #SarcomaAwareness #BoneCancerAwareness
Sarcoma and Bone Cancer Center | Dana-Farber Cancer Institute
Learn about our Sarcoma and Bone Cancer Treatment Center at Dana-Farber Cancer Institute today.
bit.ly
Dana-Farber Cancer Institute@danafarber.bsky.social · last wk.This year, an estimated 17,370 people in the U.S. will be diagnosed with sarcoma, according to @americancancersoc.bsky.social. Our healing garden glowed yellow this July for Sarcoma Awareness Month to honor everyone impacted by the disease and help raise awareness. 🎗️ @dfciayasarcoma.bsky.social
Today is World #HeadAndNeckCancer Day which raises global awareness about cancers affecting the throat, larynx, nose, sinuses and mouth and the importance of early detection. Learn about symptoms, risk factors, prevention and treatment options at bit.ly/4lrJlDg. @danafarber.bsky.social
Head and Neck Cancer: What You Should Know
Head and neck cancers represent a group of cancers that affect the throat, larynx, nose, sinuses, and mouth. These diseases are relatively rare, but they affect vital functions, including swallowing and speaking. Here are five things to know about head and neck cancer, including: - What are the risk factors for head and neck cancer?
bit.ly
We’re proud to share we earned the highest patient-rated nurse communication score among the nation's 11 dedicated cancer hospitals. This recognition reflects both the incredible work of our nurses and the collaborative culture across the Institute that supports an outstanding patient experience.
Nurse communication star ratings for 11 cancer hospitals - Becker's Oncology
Of all 11 prospective payment system-exempt cancer hospitals, Boston-based Dana-Farber Cancer Institute had the highest nurse communication score between July 1, 2024, and June 30, 2025, according to CMS data published May 13. The Hospital Consumer Assessment of Healthcare Providers and Systems is a national, standardized survey completed by patients after inpatient hospital stays. Eleven […]
bit.ly
New research in @pnas.org by @danafarber.bsky.social’s Dr. Rizwan Haq identifies a regulator that recruits active Gα proteins to the endolysosomal compartment via an evolutionarily conserved motif shared across multiple Gα proteins. Read more here: bit.ly/3Th2JJW
In Oncology Nursing News, @danafarber.bsky.social’s Simone Payette-Capone, RN, discusses balancing protocol with patient care, managing GU trial logistics, and the research nurse's role as a "detective." Read more: bit.ly/4feWdvB
GU Oncology Trial Logistics: Nursing Insights from Dana-Farber | Oncology Nursing News
Simone Payette-Capone, RN, discusses balancing protocol with patient care, managing GU trial logistics, and the research nurse's role as a "detective."
bit.ly
In a recent podcast with BBC The Inquiry, @danafarber.bsky.social’s Dr. Natasha Archer discusses gene therapy accessibility for sickle cell disease. Listen here: bit.ly/4fGVe7D
BBC Audio | The Inquiry | Are we closer to gene therapy for sickle cell disease being accessible?
Can gene therapy become accessible for people living with sickle cell disease?
bit.ly
Can a blood test improve early detection of aggressive #ProstateCancer? In Inside Precision Medicine, @danafarber.bsky.social’s Dr. Mark Pomerantz discusses research into tests like Stockholm3 and their potential to identify more high-risk cancers than PSA alone. ▶️ bit.ly/44UFckm
Stockholm3 Blood Test Detects More High-Risk Prostate Cancers Early
The Stockholm3 blood test detected more clinically significant cancer cases than the well-established, but problematic, PSA screening test.
bit.ly
In honor of #SarcomaAwarenessMonth, Suzanne George, MD, discusses @danafarber.bsky.social’s relentless efforts to promote early detection and support ongoing research to improve the lives of patients living with these rare cancers including #GIST. Watch here: bit.ly/4vI65mM
Sarcoma Awareness and Advances: Suzanne George, MD | Dana-Farber Cancer Institute
July is Sarcoma Awareness Month. In this video, Suzanne George, MD, a sarcoma expert at Dana-Farber Cancer Institute, discusses the importance of sarcoma awareness, early detection, and advancing research for rare cancers, including gastrointestinal stromal tumors (GIST). Learn how Dana-Farber is working to improve diagnosis, expand treatment options, and drive research that is improving outcomes for people living with sarcoma and GIST.
bit.ly
Unpacking the increase in early-onset cancers: @danafarber.bsky.social’s Kimmie Ng, MD, is featured in this episode of JAMA's Healthy Dialogue Podcast discussing what may be behind the rise in young-onset colorectal cancer. 🎧 Listen: ja.ma/4fNUxtP
Unpacking the Rise in Early-Onset Cancer
JAMA Senior Editor Derek C. Angus, MD, MPH, spoke with Kimmie Ng, MD, MPH, director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute, and Ilana Richman, MD, MHS, an assistant professor at the Yale School of Medicine, about the rise in early-onset cancer among younger...
ja.ma
During Sarcoma Awareness Month, a young adult with Ewing sarcoma shares her experience and why the AYA-focused care provided at Dana-Farber matters. Read her story on the Insight Blog. @danafarber.bsky.social @danafarbernews.bsky.social blog.dana-farber.org/insight/2026...
Doctor by Day, Patient by Night: Young Sarcoma Survivor Overcomes Life Interrupted
From doctor to patient, one young physician shares how an Ewing sarcoma diagnosis reshaped her life, career, and perspective on cancer care.
blog.dana-farber.org
New in Cancer Discovery: Short-term, high-dose vitamin D may reshape immune environment in #ColonCancer, supporting further study of vitamin D as a potential immune modulator. Read more from @danafarber.bsky.social researchers: bit.ly/4f4C4qJ
In a recent study published in Blood, @lane-andy.bsky.social and @danafarber.bsky.social researchers found a three-drug combination showed high remission rates in patients with rare, aggressive #BPDCN. Read more: bit.ly/3QK3WZm
In a recent @jamaoncology.com publication, @biagioricciutimd.bsky.social and @danafarber.bsky.social researchers found that first-line chemo-immunotherapy improved survival outcomes compared with PD-(L)1 inhibitor monotherapy in advanced NSCLC with PD-L1 ≥50%. Read more: bit.ly/4vVbhVh
“There’s a two-way street here. Having these teams and connections going from bench to bedside, back to bench and such, I think will speed up our ability to help patients,” F. Stephen Hodi said about the collaboration behind cancer research and care. Read more. ⬇️
Tracing evolution of vaccine for cancer, malaria — Harvard Gazette
Technology born out of Harvard labs shows the power of collaboration, and how the path to development seldom follows a straight line.
bit.ly
Brian Wolpin, MD, MPH, spoke with @wbur.org Meghna Chakrabarti about promising new research, led by Wolpin and his team, showing daraxonrasib significantly extended survival for patients with previously treated metastatic pancreatic cancer. Listen here. ⬇️
The pill bringing new hope to patients with pancreatic cancer
Pancreatic cancer has long been considered a death sentence. But a revolutionary new treatment has been shown to double survival times.
bit.ly
Now in @jco-asco.bsky.social from @danafarber.bsky.social: The eNRGy phase 2 clinical trial improved progression-free survival for previously treated patients with advanced NRG1-positive cholangiocarcinoma. This study led to FDA approval for zenocutuzumab for this population. bit.ly/4eAItuT
In a @natchembio.nature.com study, @danafarber.bsky.social researchers report the first selective IRF4 degrader, a promising preclinical strategy against multiple myeloma. Read more: bit.ly/4va1HfQ
Dana-Farber Investigators Formulate First IRF Degrader with Potential for Multiple Myeloma
RESEARCH SUMMARYStudy Title: Pharmacological Targeting of IRF4 as a Therapeutic Strategy for Multiple MyelomaPublication: Nature Chemical BiologyDana-Farber Cancer Institute authors: Irene Ghobrial, MD, Jun Qi, PhD
bit.ly
July is #SarcomaAwarenessMonth, a time to raise awareness about this rare cancer that affects connective tissues such as bone, muscle, blood vessels, nerves, and fat. Learn more about risk factors, signs and symptoms, diagnosis, and treatment options at @danafarber.bsky.social at bit.ly/4gLBznV
Sarcoma and Bone Cancer Types
Get information about soft tissue sarcomas, types of bone cancer, and other related conditions.
bit.ly
More Than Medicine: The Power of Trust Between Patient and Doctor. In @curetoday.bsky.social, Chuck Stravin reflects on the lifelong bond he's built with @drchoueiri.bsky.social and how that trust has shaped his #KidneyCancer journey. ➡️bit.ly/3QF87FI
David Shulman, MD, Director of the Dana-Farber AYA Sarcoma Program, discusses a newly opened phase 1/2 trial of LNTH-2403, an LRRC15-targeted radiopharmaceutical, for relapsed/refractory osteosarcoma. @danafarber.bsky.social @danafarbernews.bsky.social www.youtube.com/watch?v=vQ1a...
OsteoBites | Phase 1/2 Study of LNTH 2403 for Relapsed Osteosarcoma
YouTube video by Osteosarcoma: MIB Agents Osteosarcoma Alliance
youtube.com
Research presented by Nadine Jackson, MD, MPH, of @danafarber.bsky.social shows older adults with GI cancer who are frail and face social/health literacy challenges may be at greater risk for poor outcomes, underscoring the importance of personalized support and care. #ASCOBT26 bit.ly/4gkMLYL
Congratulations to Matthew Leventhal, PhD, a researcher in @danafarber.bsky.social's Pellman and Zhang labs who has been named a Quantitative Biology Fellow by @damonrunyon.org for his work to identify new drivers of cancer on the X chromosome. ➡️bit.ly/4fOX9HR
